Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Inclusion Criteria: 1. Age ≥18 years old; 2. Acute anterior circulation large artery atherosclerotic cerebral infarction (according to TOAST classification) within 48h of onset; NIHSS score ≥6, ≤15; 3. Moderate to severe stenosis or occlusion of offending vessels; 4. The mRS Score ≤2 before onset; 5. Subjects or their legal representatives agreed to the treatment and signed the informed consent form. Exclusion Criteria: 1. Transient ischemic attack; 2. Patients who planned or had received emergency reperfusion therapy (including intravenous thrombolysis and emergency thrombectomy); 3. Severe disturbance of consciousness:GCS ≤8; 4. Patients who previously received angiotensin-converting enzyme inhibitor (ACEI) drugs regularly; 5. Refractory hypertension: systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg; hypotension: systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg; 6. Liver dysfunction (ALT/AST \>1.5 × upper limit of normal \[ULN\]), renal dysfunction (Cr \>1 × ULN); 7. Coagulopathy (prolonged INR (\>1.5) or prolonged APTT (\>2 folds); 8. Cardioembolic stroke or high-risk factors of cardioembolic stroke identified by investigators (atrial fibrillation, cardiac mural thrombus, cardiomyopathy, etc.); 9. Special populations such as pregnant and lactating women, patients with life expectancy less than 3 months, or patients unable to complete the study for other reasons; 10. Unwilling to be followed up or poor treatment compliance; 11. Participating in other clinical investigators, or had participated in other clinical investigators within 3 months before enrollment; 12. Other conditions considered by the investigator to be inappropriate for enrollment.